Search clinical trials for: TB relapse

Total 10055 results

The First Affiliated Hospital of Soochow University

Recruiting

TBI/Flu/Bu/Mel Combined With Secondary UCBT in Patients With Hematological Malignancies Who Relapsed After Allo-HSCT

Hematopoietic Stem Cell Transplantation | Relapse/Recurrence | Hematopoietic Malignancy

China
Boston Medical Center
The International Union Against Tuberculosis and Lung Disease

Recruiting

The INSTITUT Study (INSTITUT)

Tuberculosis, Pulmonary | Undernutrition

Benin, Togo
University of Birmingham
Regeneron Pharmaceuticals; Cancer Research UK; Fight Kids Cancer; ADC Therapeutics...

Not yet recruiting

A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma (Glo-BNHL)

B-cell Non Hodgkin Lymphoma
University Health Network, Toronto
Takara Bio Inc.

Recruiting

Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL

Relapsed or Refractory Chronic Lymphocytic Leukemia | Relapsed or Refractory Small Lymphocytic Lymphoma | Relapsed or Refractory CD19+ B-cell Lymphoma

Canada
Masonic Cancer Center, University of Minnesota

Recruiting

Allo HSCT Using RIC and PTCy for Hematological Diseases

Follicular Lymphoma | Myelodysplastic Syndromes | Leukemia, Myeloid | Myelofibrosis | Burkitt Lymphoma | Marginal Zone Lymphoma | Acute Lymphocytic Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Prolymphocytic Leukemia | Plasma Cell Leukemia | Myeloproliferative Neoplasm | Small Lymphocytic... and other conditions

United States
H. Lee Moffitt Cancer Center and Research Institute
Turnstone Biologics, Corp.

Recruiting

Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma

Metastatic Melanoma | Conjunctival Melanoma | Ocular Melanoma | Unresectable Melanoma | Uveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma | Iris Melanoma | Acral Melanoma | Non-Cutaneous Melanoma

United States
The Hong Kong Polytechnic University

Not yet recruiting

Predicting Illness Trajectories In Fully Remitted Major Depression Using Concurrent TBS/fNIRS (TBS/fNIRS)

Healthy | Major Depression in Remission
PharmaMar

Recruiting

Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)

Relapsed Small Cell Lung Cancer

United States, Spain, Japan, Korea, Republic of, United Kingdom, Israel, France, Taiwan, Germany, Australia, Belgium, Georgia, Italy, Switzerland, Denmark, Hungary, Poland, Romania, Canada, Brazil, Bulgaria, Austria, Chile, Turkey
Novartis Pharmaceuticals

Recruiting

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)

Relapsing Multiple Sclerosis

China, Spain, Switzerland, Taiwan, United States, Italy, Austria, Belgium, Saudi Arabia, United Arab Emirates, Latvia, Poland, Argentina, India, Croatia, Bulgaria, Malaysia, Slovakia, Israel, Lebanon, Guatemala, Netherlands, Colombia, Chil... and more
Genmab

Recruiting

GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies

Acute Myeloid Leukemia (AML) | Diffuse Large B Cell Lymphoma (DLBCL) | Relapsed or Refractory Multiple Myeloma (RRMM)

United States, Korea, Republic of, Netherlands, Denmark, Australia, New Zealand, Poland, Spain, Sweden, Czechia, Malaysia, Greece, Moldova, Republic of, Georgia, Ukraine, France, Hungary, North Macedonia, Bosnia and Herzegovina
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Recruiting

CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

Recurrent Acute Myeloid Leukemia | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic Syndrome | Refractory Mixed Phenotype Acute Leukemia | Refractory Acute Leukemia... and other conditions

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...

Recruiting

Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Refractory and/or Relapsed Metastatic Solid Tumors

United States
TG Therapeutics, Inc.

Active, not recruiting

An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis

Relapsing Multiple Sclerosis (RMS)

United States, Belarus, Croatia, Georgia, Poland, Russian Federation, Serbia, Ukraine
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Suspended

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

Hematopoietic and Lymphoid Cell Neoplasm | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts | Recurrent Acute Lymphoblastic... and other conditions

United States
H. Lee Moffitt Cancer Center and Research Institute

Active, not recruiting

Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Hodgkin Lymphoma | Burkitt Lymphoma | Acute Lymphoblastic Leukemia | Mantle Cell Lymphoma | Lymphoplasmacytic Lymphoma | Chronic Myelogenous Leukemia | Prolymphocytic Leukemia | Myeloproliferative Neoplasm | Relapsed Follicular Lymphoma | Relapsed T-Cell Lymphoma and other conditions

United States
National Institute of Allergy and Infectious Diseases...

Completed

Using Biomarkers to Predict TB Treatment Duration

Pulmonary Tuberculosis

South Africa
Masonic Cancer Center, University of Minnesota

Active, not recruiting

Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy

Acute Myeloid Leukemia | Hodgkin Lymphoma | Burkitt Lymphoma | Mantle Cell Lymphoma | Lymphoplasmacytic Lymphoma | Acute Lymphocytic Leukemia | Chronic Myelogenous Leukemia | Myelodysplasia | Relapsed T-Cell Lymphoma | Relapsed Large Cell Lymphoma | Biphenotypic/Undifferentiated Leukemia

United States
Institute of Tropical Medicine, Belgium
Damien Foundation

Active, not recruiting

Novel Triple-dose Tuberculosis Retreatment Regimen (Tri-Do-Re)

Tuberculosis | Pulmonary Tuberculosis | Multidrug-resistant Tuberculosis | Resistance to Tuberculostatic Drugs

Niger
Therapeutic Advances in Childhood Leukemia Consortium
Genzyme, a Sanofi Company

Completed

Clofarabine and Low Dose Total Body Irradiation as a Preparative Regimen for Stem Cell Transplant in Leukemia.

Acute Myeloid Leukemia | Leukemia Lymphoblastic, Acute | Neoplasm Recurrent

United States
Takara Bio Inc.

Active, not recruiting

Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia (TBI-1501)

Lymphoblastic Leukemia, Acute Adult

Japan
Noah Merin
Teva Branded Pharmaceutical Products R&D, Inc.; Miltenyi Biomedicine GmbH

Active, not recruiting

Haploidentical Stem Cell Transplant With Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL

Lymphoma | Multiple Myeloma | Hodgkin Lymphoma | Chronic Lymphocytic Leukemia | CLL

United States
ARCAGY/ GINECO GROUP
Tesaro, Inc.

Completed

NIraparib and Quality Of LifE is a Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib. (NiQoLe)

Ovarian Cancer

France
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Terminated

Reduced-Intensity Regimen Before Allogeneic Transplant for Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma

Lymphoma

United States
Oncopeptides AB

Terminated

Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma (LIGHTHOUSE)

Relapsed Multiple Myeloma | Relapsed-Refractory Multiple Myeloma

Serbia, Greece, Russian Federation, Czechia, Bulgaria, Georgia, Norway, Poland, Spain, Ukraine, Germany
Masonic Cancer Center, University of Minnesota

Active, not recruiting

UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep

Follicular Lymphoma | Acute Myeloid Leukemia | Multiple Myeloma | Hodgkin Lymphoma | Lymphoplasmacytic Lymphoma | Acute Leukemia | Myelodysplastic Syndrome | Chronic Myelogenous Leukemia | Prolymphocytic Leukemia | Plasma Cell Leukemia | Bone Marrow Failure Syndromes | Burkitt's Lymphoma | Acute Lymphoblastic Leukemia... and other conditions

United States
Molecular Templates, Inc.

Terminated

Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL (MT-3724NHL001)

Leukemia, Lymphocytic, Chronic, B-Cell | Diffuse Large B Cell Lymphoma | Blood Cancer | Hematological Malignancy | Small Lymphocytic Leukemia | Non-Hodgkin's B-cell Lymphoma

United States, Canada, Georgia, Belarus, Spain, Israel, Moldova, Republic of, Poland, Serbia, Ukraine
VA Office of Research and Development

Completed

Simvastatin for mTBI

TBI-Traumatic Brain Injury

United States
Shanghai Mental Health Center

Completed

Transcranial Magnetic Stimulation for Treatment of Methamphetamine Use Disorder

Amphetamine Use Disorders

China
Rhizen Pharmaceuticals SA

Completed

Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Leukemia, Lymphocytic, Chronic, B-Cell

Georgia, Bulgaria, Poland
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma

Recurrent Adult Diffuse Large Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Post-Transplant Lymphoproliferative Disorder | Recurrent Burkitt Lymphoma | Refractory Burkitt Lymphoma

United States
Tuberculosis Research Centre, India
National Institutes of Health (NIH)

Completed

Latency in Pulmonary Tuberculosis

Pulmonary Tuberculosis

India
Oncurious NV
Beat Childhood Cancer

Completed

A Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma

Relapsed or Refractory Medulloblastoma (MB), Neuroblastoma (NB), Ewing Sarcoma (ES) and Alveolar Rhabdomyosarcoma (ARMS)

United States
United Therapeutics

Completed

Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer

Small Cell Lung Cancer

United States, Canada, Spain, Australia, Korea, Republic of, France, United Kingdom, Thailand, Malaysia, Hungary, Poland, Taiwan, Philippines, Hong Kong, Lithuania, Georgia, Bulgaria, India, Italy, Romania, Russian Federation, Slo... and more
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Intra-Osseous Co-Transplant of UCB and hMSC

Myelodysplastic Syndromes | Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Myelofibrosis | Acute Lymphoblastic Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Refractory Chronic Lymphocytic Leukemia | Refractory Non-Hodgkin Lymphoma | Lymphoid Malignancies | Relapsed Non-Hodgkin Lymphoma and other conditions

United States
Takeda

Terminated

A Study of MLN9708 in Japanese Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)

Relapsed and/or Refractory Multiple Myeloma
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | de Novo Myelodysplastic Syndrome | Acute Biphenotypic Leukemia

United States
University of Wisconsin, Madison
National Cancer Institute (NCI)

Completed

Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult... and other conditions

United States
Yonsei University

Withdrawn

Safety and Immunogenicity Study of GX-70 in TB Patient

Pulmonary Tuberculoses | Treatment Failure | High Risk Factors for Relapse
Washington University School of Medicine

Terminated

Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Leukemia, Myeloid, Acute

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma | Recurrent Adult Immunoblastic Large Cell Lymphoma | Recurrent Adult Lymphoblastic... and other conditions

United States
Masonic Cancer Center, University of Minnesota

Terminated

Chemotherapy, Total-Body Irradiation, Donor Natural Killer Cell Infusion, Aldesleukin, and UCB Transplant in Treating Patients With Relapsed or Refractory AML

Leukemia

United States
National Cancer Institute (NCI)

Withdrawn

Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Recurrent Childhood Acute Myeloid Leukemia | CNS 2a | CNS 2b | CNS 2c | CNS1
Synthon BV

Completed

Efficacy and Safety of GTR in Comparison to Copaxone® (GATE)

Multiple Sclerosis

United States, Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia, Georgia, Germany, Italy, Mexico, Moldova, Republic of, Poland, Romania, Russian Federation, Serbia, South Africa, Ukraine, United Kingdom
Chinese University of Hong Kong
Guangzhou Institute of Respiratory Disease

Completed

Directly Observed Therapy Short Course-Plus Versus DOTS for Retreatment of Relapsed Pulmonary Tuberculosis in Guangzhou

Pulmonary Tuberculosis

China
Azienda Ospedaliera San Giovanni Battista

Unknown

Thiotepa, Busulfan and Fludarabin for pt With Refractory/Early Relapsed Aggressive B-cell Non Hodgkin Lymphomas (TBF)

B-cell Lymphoma Refractory

Italy
Poniard Pharmaceuticals

Unknown

Study of Picoplatin Efficacy After Relapse (SPEAR)

Small Cell Lung Cancer

India, Russian Federation, Argentina, Belarus, Bosnia and Herzegovina, Bulgaria, Chile, Croatia, Hungary, Latvia, Montenegro, Poland, Romania, Serbia, Ukraine
Ontario Clinical Oncology Group (OCOG)
Pfizer

Not yet recruiting

Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma (EMBRACE)

Refractory Multiple Myeloma

Canada
Second Affiliated Hospital, School of Medicine,...

Not yet recruiting

Anti-CD19 CAR-NK Cells in Refractory/Relapsed Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

China
National Research Center for Hematology, Russia
St. Petersburg State Pavlov Medical University; Federal State Budgetary Institution...

Recruiting

IMPACT-AML: Randomized Pragmatic Clinical Trial for Relapsed or Refractory AML

Refractory Acute Myeloid Leukemia | Early Relapses of Acute Myeloid Leukemia

Russian Federation
The University of Hong Kong

Recruiting

A Prospective Evaluation of Radiofrequency Ablation in the Treatment of Relapsed Graves' Disease.

Thyroid; Functional Disturbance | Relapsed Graves' Disease | Radiofrequency Ablation Treatment

Hong Kong

Search clinical trials for: TB relapse

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritius

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations